1. Home
  2. NVAX vs IMKTA Comparison

NVAX vs IMKTA Comparison

Compare NVAX & IMKTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • IMKTA
  • Stock Information
  • Founded
  • NVAX 1987
  • IMKTA 1963
  • Country
  • NVAX United States
  • IMKTA United States
  • Employees
  • NVAX N/A
  • IMKTA N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • IMKTA Food Chains
  • Sector
  • NVAX Health Care
  • IMKTA Consumer Staples
  • Exchange
  • NVAX Nasdaq
  • IMKTA Nasdaq
  • Market Cap
  • NVAX 1.3B
  • IMKTA 1.2B
  • IPO Year
  • NVAX 1995
  • IMKTA N/A
  • Fundamental
  • Price
  • NVAX $6.84
  • IMKTA $66.93
  • Analyst Decision
  • NVAX Buy
  • IMKTA
  • Analyst Count
  • NVAX 5
  • IMKTA 0
  • Target Price
  • NVAX $16.60
  • IMKTA N/A
  • AVG Volume (30 Days)
  • NVAX 4.9M
  • IMKTA 115.9K
  • Earning Date
  • NVAX 08-07-2025
  • IMKTA 08-07-2025
  • Dividend Yield
  • NVAX N/A
  • IMKTA 0.98%
  • EPS Growth
  • NVAX N/A
  • IMKTA N/A
  • EPS
  • NVAX 2.97
  • IMKTA 3.26
  • Revenue
  • NVAX $1,254,962,000.00
  • IMKTA $5,410,455,724.00
  • Revenue This Year
  • NVAX $56.85
  • IMKTA N/A
  • Revenue Next Year
  • NVAX N/A
  • IMKTA N/A
  • P/E Ratio
  • NVAX $2.30
  • IMKTA $20.55
  • Revenue Growth
  • NVAX 25.92
  • IMKTA N/A
  • 52 Week Low
  • NVAX $5.01
  • IMKTA $58.92
  • 52 Week High
  • NVAX $17.81
  • IMKTA $82.01
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 51.12
  • IMKTA 67.20
  • Support Level
  • NVAX $6.54
  • IMKTA $65.44
  • Resistance Level
  • NVAX $7.20
  • IMKTA $66.64
  • Average True Range (ATR)
  • NVAX 0.28
  • IMKTA 1.47
  • MACD
  • NVAX 0.06
  • IMKTA 0.35
  • Stochastic Oscillator
  • NVAX 66.36
  • IMKTA 85.40

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About IMKTA Ingles Markets Incorporated

Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.

Share on Social Networks: